- Home
- PBA vs TEVA Comparison
PBA vs TEVA Comparison
Compare PBA & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- TEVA
- Stock Information
- Founded
- PBA 1997
- TEVA 1901
- Country
- PBA Canada
- TEVA Israel
- Employees
- PBA N/A
- TEVA N/A
- Industry
- PBA Oil & Gas Production
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- PBA Energy
- TEVA Health Care
- Exchange
- PBA Nasdaq
- TEVA Nasdaq
- Market Cap
- PBA 21.0B
- TEVA 23.7B
- IPO Year
- PBA N/A
- TEVA N/A
- Fundamental
- Price
- PBA $36.37
- TEVA $17.06
- Analyst Decision
- PBA Buy
- TEVA Buy
- Analyst Count
- PBA 1
- TEVA 7
- Target Price
- PBA $59.00
- TEVA $22.29
- AVG Volume (30 Days)
- PBA 1.4M
- TEVA 13.5M
- Earning Date
- PBA 02-27-2025
- TEVA 01-29-2025
- Dividend Yield
- PBA 5.49%
- TEVA N/A
- EPS Growth
- PBA 51.43
- TEVA N/A
- EPS
- PBA 2.43
- TEVA N/A
- Revenue
- PBA $7,305,229,650.00
- TEVA $16,544,000,000.00
- Revenue This Year
- PBA N/A
- TEVA $5.80
- Revenue Next Year
- PBA $13.47
- TEVA $1.15
- P/E Ratio
- PBA $15.00
- TEVA N/A
- Revenue Growth
- PBA 37.18
- TEVA 4.40
- 52 Week Low
- PBA $32.81
- TEVA $11.83
- 52 Week High
- PBA $43.44
- TEVA $22.80
- Technical
- Relative Strength Index (RSI)
- PBA 44.42
- TEVA 26.54
- Support Level
- PBA $34.76
- TEVA $17.51
- Resistance Level
- PBA $37.29
- TEVA $22.40
- Average True Range (ATR)
- PBA 0.67
- TEVA 0.70
- MACD
- PBA -0.02
- TEVA -0.64
- Stochastic Oscillator
- PBA 48.49
- TEVA 1.11
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its assets include pipelines and gas gathering as well as assets across fractionation, storage, and propane exports.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.